Taiwan Liposome Company is a biotechnology business based in the US. Taiwan Liposome Company shares (TLC) are listed on the NASDAQ and all prices are listed in US Dollars.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| 52-week range | $0.00 - $0.00 |
|---|---|
| 50-day moving average | $7.16 |
| 200-day moving average | $6.37 |
| Wall St. target price | $9.25 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.67 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
| Revenue TTM | $276 million |
|---|---|
| Gross profit TTM | $101.9 million |
| Return on assets TTM | -34.73% |
| Return on equity TTM | -108.77% |
| Profit margin | -283.11% |
| Book value | $4.19 |
| Market Capitalization | $302.8 million |
TTM: trailing 12 months
We're not expecting Taiwan Liposome Company to pay a dividend over the next 12 months.
Taiwan Liposome Company's shares were split on a 506:503 basis on 9 June 2020 . So if you had owned 503 shares the day before before the split, the next day you'd have owned 506 shares. This wouldn't directly have changed the overall worth of your Taiwan Liposome Company shares – just the quantity. However, indirectly, the new 0.6% lower share price could have impacted the market appetite for Taiwan Liposome Company shares which in turn could have impacted Taiwan Liposome Company's share price.
Over the last 12 months, Taiwan Liposome Company's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Taiwan Liposome Company's is 0.7972. This would suggest that Taiwan Liposome Company's shares are less volatile than average (for this exchange).
Taiwan Liposome Company, Ltd. , a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). The BioSeizer lipid formulation technology is designed to enable local sustained release and fast onset of APIs at the site of disease or injury with enhanced pharmacokinetic (PK) control by customization of lipid layers; and NanoX active drug loading technology enables the potential for reduced dosing frequency and enhanced distribution of liposome-encapsulated APIs to the desired site. Its lead product candidate is TLC599, an intraarticular injectable BioSeizer formulation of the API steroid dexamethasone sodium phosphate (DSP), which is in Phase III clinical trial for the treatment of knee osteoarthritis pain. The company's product candidates also comprise TLC590, a non-opioid BioSeizer formulation of the API ropivacaine that has completed Phase II clinical trial to treat post-surgical pain; TLC399, a multilamellar and multivesicular BioSeizer formulation of DSP, which is in Phase II clinical trial for ophthalmology indications; TLC178, an API that is in Phase I/II dose escalation trial to treat rhabdomyosarcoma; and TLC19 that is in Phase I clinical trial to treat COVID-19. Taiwan Liposome Company, Ltd. was founded in 1997 and is headquartered in Taipei, Taiwan.
These are the stocks to buy when you don’t have much to spend.
Cash sweep accounts let you earn interest on your uninvested cash. Learn how they work and how to choose the best one here.
These are the best day trading apps, according to Finder’s comprehensive analysis.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Compare pros, cons, research tools and reviews for these two trading platforms.
Fractional shares are fractions of company shares. Sometimes they’re made by brokers to allow those with limited funds to get access to stocks.
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.